<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5301">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03037931</url>
  </required_header>
  <id_info>
    <org_study_id>1VIT15043</org_study_id>
    <nct_id>NCT03037931</nct_id>
  </id_info>
  <brief_title>Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency</brief_title>
  <acronym>HEART-FID</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luitpold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Luitpold Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the efficacy and safety of iron therapy
      using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo, in the treatment of
      participants in heart failure with iron deficiency and with a reduced ejection fraction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, multicenter, prospective, randomized, placebo-controlled study to
      assess the effects of IV FCM compared to placebo on the 12-month rate of death,
      hospitalization for worsening heart failure, and the 6-month change in 6 minute walk test
      (6MWT) for patients in heart failure with iron deficiency.

      After an initial screening period of up to 28 days, eligible participants will be stratified
      by region and randomized in a 1:1 ratio to FCM or placebo for treatment.

      Study drug administration will occur on Day 0 and Day 7 (±2) as an undiluted slow IV push,
      with additional study visits planned at 3 month intervals, and additional dosing
      administered every 6 months as applicable. In a subset of sites, all participants will
      return for recurrent laboratory assessment (chemistry, hematology and iron indices) at Day
      21 (± 7) after each course of investigational treatment. For all participants, hematology,
      ferritin, and transferrin saturation (TSAT), with appropriate safety evaluations, to
      determine additional treatment, will occur at 6 month intervals.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Death</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of hospitalization for heart failure</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 6MWT distance</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3014</enrollment>
  <condition>Heart Failure</condition>
  <condition>Iron-deficiency</condition>
  <arm_group>
    <arm_group_label>Ferric Carboxymaltose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ferric Carboxymaltose 2 doses intravenously of 15mg/kg to a maximum individual dose of 750mg 7 days apart and a maximum combined dose of 1500mg - repeated every 6 months as indicated by iron indices</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebos</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline 15ml - 2 doses 7 days apart repeated every 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric carboxymaltose</intervention_name>
    <description>Intravenous Iron</description>
    <arm_group_label>Ferric Carboxymaltose</arm_group_label>
    <other_name>Injectafer, Ferinject</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Normal Saline Solution</description>
    <arm_group_label>Placebos</arm_group_label>
    <other_name>Saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult (≥18 years of age) able to provide informed consent.

          2. Stable heart failure (NYHA II-IV) on maximally-tolerated background therapy (as
             determined by the site Principle Investigator) for at least 4 weeks with no dose
             changes in heart failure drugs during the last 2 weeks.

          3. Able and willing to perform a 6MWT at the time of randomization.

          4. Reduced left ventricular ejection fraction. Assessment must be performed at least 12
             weeks after major cardiac surgical intervention including coronary artery bypass
             graft (CABG), valvular repair/replacement, or cardiac resynchronization therapy (CRT)
             device implantation.

             a. Left ventricular ejection fraction ≤35% obtained during the screening visit OR
             either of the following i. Historical value of ejection fraction ≤35% within 12
             months of screening visit ii. Historical value of ejection fraction ≤25% within 24
             months of screening visit

          5. Hemoglobin &gt;9.0 g/dL and &lt;13.5 g/dL (females) or &lt;15.0 g/dL (males).

          6. Serum ferritin &lt;100 ng/mL or 100 to 300 ng/mL with TSAT &lt;20%.

          7. Either documented hospitalization for heart failure within 12 months of enrollment or
             screening visit N-terminal-pro-brain natriuretic peptide (NT-proBNP) &gt;600 pg/ml (or
             BNP &gt;200 pg/mL) for patients with normal sinus rhythm or NT-proBNP &gt;1000 pg/ml (or
             BNP &gt;400 pg/mL) for patients with atrial fibrillation. NOTE: NT-proBNP must be used
             to confirm eligibility for patients taking sacubitril/valsartan.

        Exclusion Criteria:

          1. Current or planned oral iron supplementation. Iron-containing multivitamins (&lt;30 mgs
             /day) are permitted.

          2. Known hypersensitivity reaction to any component of FCM.

          3. History of acquired iron overload, or the recent receipt (within 3 months) of
             erythropoietin stimulating agent, IV iron therapy, or blood transfusion.

          4. Acute myocardial infarction, acute coronary syndrome, transient ischemic attack, or
             stroke within 3 months of enrollment.

          5. Uncorrected severe aortic stenosis, severe valvular regurgitation, or left
             ventricular outflow obstruction requiring intervention.

          6. Current atrial fibrillation or atrial flutter with a mean ventricular response rate
             &gt;100 per minute (at rest).

          7. Current or planned mechanical circulatory support or heart transplantation.

          8. Hemodialysis or peritoneal dialysis (current or planned within the next 6 months).

          9. Documented liver disease, or active hepatitis (i.e. alanine transaminase or aspartate
             transaminase &gt;3 times the upper limit of normal range).

         10. Current or recent (within 3 years) malignancy with exception of basal cell carcinoma
             or squamous cell carcinoma of the skin, or cervical intraepithelial neoplasia.

         11. Known gastrointestinal bleeding. Patients with screening ferritin &lt;15ng/ml must have
             an appropriate evaluation within 3 months of screening.

         12. Female participant of child-bearing potential who is pregnant, lactating, or not
             willing to use adequate contraceptive precautions during the study and for up to 5
             days after the last scheduled dose of study medication.

         13. Inability to return for follow up visits within the necessary windows
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian F Hernandez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Todd Koch</last_name>
    <phone>610-650-4200</phone>
    <email>tkoch@lpicrd.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sumita Chowdhury, MD</last_name>
    <phone>610-650-4200</phone>
    <email>schowdhury@lpicrd.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>William Ross Davis, MD</name>
      <address>
        <city>Alexander City</city>
        <state>Alabama</state>
        <zip>35010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Forbus, RN BSN</last_name>
      <phone>256-215-5323</phone>
      <email>s.forbus.adv@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samuel M. Butman, MD</name>
      <address>
        <city>Cottonwood</city>
        <state>Arizona</state>
        <zip>86326</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Bigelow, RN BSN</last_name>
      <phone>928-639-5306</phone>
      <email>Alicia.bigelow@nahealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Masoud M Azizad, MD</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Toven</last_name>
      <phone>818-280-4220</phone>
      <email>julie@valleyclinicaltrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jonathan Fialkow, MD</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Calvo</last_name>
      <phone>305-275-8808</phone>
      <email>mcalvo@cardioresearchmiami.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Misal Khan, MD</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Misal Khan, MD</last_name>
      <phone>850-785-9511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neerav Suresh Shah, MD</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Dagher</last_name>
      <phone>561-906-4161</phone>
      <email>Elizabeth.dagher@cardiologypartnerspl.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ehab Sorial, MD</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02721</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Francoeur</last_name>
      <phone>508-672-7450</phone>
      <phone_ext>22</phone_ext>
      <email>lfrancoeur@neccr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lance Berger, MD</name>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Allfrey</last_name>
      <phone>732-807-2170</phone>
      <email>aallfrey@monmouthcardiology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vipul Shah, MD</name>
      <address>
        <city>Lancaster</city>
        <state>South Carolina</state>
        <zip>29720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emad Ghaly</last_name>
      <phone>803-285-2041</phone>
      <email>Eghaly1@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Martin R. Berk, MD</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Daniel</last_name>
      <phone>214-360-0869</phone>
      <email>ddaniel@civadallas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mohammad Fawwaz Shoukfeh, MD</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Hays</last_name>
      <phone>806-797-1885</phone>
      <email>khays@txcardiac.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elie Gharib, MD</name>
      <address>
        <city>South Charleston</city>
        <state>West Virginia</state>
        <zip>25309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 30, 2017</lastchanged_date>
  <firstreceived_date>January 25, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
